期刊文献+

Impact of Different Embolic Agents for Transarterial Chemoembolization (TACE) Procedures on Systemic Vascular Endothelial Growth Factor (VEGF) Levels 被引量:15

Impact of Different Embolic Agents for Transarterial Chemoembolization (TACE) Procedures on Systemic Vascular Endothelial Growth Factor (VEGF) Levels
原文传递
导出
摘要 Background and Aims:Intermediate stage hepatocellular carcinoma (HCC) can be treated by transarterial chemoem-bolization (TACE).However,there appear to be side effects,such as induction of proangiogenic factors,e.g.vascular endothelial growth factor (VEGF),which have been shown to be associated with a poor prognosis.This prospective study was designed to compare serum VEGF level response after TACE with different embolic agents in patients with HCC.Methods:Patients were assigned to one of three different TACE regimens:degradable starch microspheres (DSM) TACE,drugeluting bead (DEBDOX) TACE or Lipiodol TACE (cTACE).All patients received 50 mg doxorubicin/m2 body surface area (BSA) during TACE.Serum VEGF levels were assessed before TACE treatment,24 h post-treatment and 4 weeks later.Results:Twenty-two patients with 30 TACE treatments were enrolled.Compared to baseline VEGF levels,a marked increase was observed for 24 h post-TACE (164% of baseline level) and during the 4-week follow-up (170% of baseline level) only for the cTACE arm (p < 0.05).In contrast,the increase of serum VEGF levels were only 114% and 123% for DEBDOX and 121% and 124% for DSM,respectively.Conclusions:Conventional TACE using Lipiodol shows marked increase in blood levels of the proangiogenic factor VEGF,while DEBDOX and DSM TACE induce only a moderate VEGF response. Background and Aims:Intermediate stage hepatocellular carcinoma (HCC) can be treated by transarterial chemoem-bolization (TACE).However,there appear to be side effects,such as induction of proangiogenic factors,e.g.vascular endothelial growth factor (VEGF),which have been shown to be associated with a poor prognosis.This prospective study was designed to compare serum VEGF level response after TACE with different embolic agents in patients with HCC.Methods:Patients were assigned to one of three different TACE regimens:degradable starch microspheres (DSM) TACE,drugeluting bead (DEBDOX) TACE or Lipiodol TACE (cTACE).All patients received 50 mg doxorubicin/m2 body surface area (BSA) during TACE.Serum VEGF levels were assessed before TACE treatment,24 h post-treatment and 4 weeks later.Results:Twenty-two patients with 30 TACE treatments were enrolled.Compared to baseline VEGF levels,a marked increase was observed for 24 h post-TACE (164% of baseline level) and during the 4-week follow-up (170% of baseline level) only for the cTACE arm (p < 0.05).In contrast,the increase of serum VEGF levels were only 114% and 123% for DEBDOX and 121% and 124% for DSM,respectively.Conclusions:Conventional TACE using Lipiodol shows marked increase in blood levels of the proangiogenic factor VEGF,while DEBDOX and DSM TACE induce only a moderate VEGF response.
出处 《Journal of Clinical and Translational Hepatology》 SCIE 2016年第4期288-292,共5页 临床与转化肝病杂志(英文版)
关键词 Transarterial chemoembolization Vascular endothelial growth factor Embolic agents Hepatocellular carcinoma ANGIOGENESIS Transarterial chemoembolization Vascular endothelial growth factor Embolic agents Hepatocellular carcinoma Angiogenesis
  • 相关文献

参考文献5

二级参考文献75

  • 1Zhen-Dong Xu, Hai-Tao Xu, Hong-Bin Yuan, Hao Zhang, Rui-Hua Ji, Zui Zou, Zhi-Ren Fu and Xue-Yin Shi Department of Anesthesiology, Huashan Hospital, Fudan University, Shanghai 200040, China ,Department of Anesthesiology ,Organ Transplantation Center , Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.Postreperfusion syndrome during orthotopic liver transplantation:a single-center experience[J].Hepatobiliary & Pancreatic Diseases International,2012,11(1):34-39. 被引量:16
  • 2Li J;Wang WL;Liu B.Angiogenesis and apoptosis in human hepatocellular carcinoma,1998.
  • 3Folkman J.Clinical application of research on angiogenesis,1995.
  • 4Baker CH,Solorzano CC,Fidler IJ,et al.Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Research . 2002
  • 5Kenji Jin-no,Masahito Tanimizu,Ichinosuke Hyodo,Yoshiyuki Nishikawa,Yasushi Hosokawa,Toshihiko Doi,Hisashi Endo,Tetsuji Yamashita,Yoshio Okada.Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma[J]. Journal of Gastroenterology . 1998 (3)
  • 6Jinno K,Tanimizu M,Hyodo I,et al.Circulating vascular endothelial growth factor ( VEGF ) is a possible tumor marker for metastasis in human hepatocellular carcinoma. Journal of Gastroenterology . 1998
  • 7Kim Margolin D.Inhibition of vascular endothelial growth factor in the treatment of solid tumors[J]. Current Oncology Reports . 2002 (1)
  • 8Wang F,Tian YH,Li L.XF inhibitation of tumor angiogene- sis, growth and metastasis by blocking VEGF paracrine path- way. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao(Shanghai) . 2002
  • 9Rosen LS.Clinical experience with angiogenesis signaling in- hibitors : focus on vascular endothelial growth factor ( VEGF) blockers. Cancer Control . 2002
  • 10Kane M,Furu T,Takena K.A 5-year experience of lipiodoli- zation: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology . 1989

共引文献129

同被引文献98

引证文献15

二级引证文献102

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部